MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Medical Imaging (Radiation Oncology, Radiation Therapy, RadioPharmaceuticals & Proton Beam) Companies
Cerenome (CNSY), formerly, Plus Therapeutics, Inc. (Nasdaq: PSTV)*
Organization & Developments: Plus Therapeutics
Parents
Cerenome (CNSY), formerly, Plus Therapeutics, Inc. (Nasdaq: PSTV)*
Children
*Lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
*Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for adults and children with rare and difficult-to-treat cancers.
2022: Plus Therapeutics (PSTV) Investor Presentation- Slideshow_seekingalpha.com
2022: Plus Therapeutics awarded a $17.6 million Product Development Research grant by the Cancer Prevention and Research Institute of Texas (CPRIT).
Jumps
Finance & Acquisitions: Plus Therapeutics
Key People: Plus Therapeutics